SBT 8230
Alternative Names: Asgr1-Tlr8; Asgr1-Tlr8-S; SBT-8230Latest Information Update: 14 Nov 2022
Price :
$50 *
At a glance
- Originator Silverback Therapeutics
- Developer ARS Pharmaceuticals
- Class Antivirals; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Toll-like receptor 8 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 08 Nov 2022 Silverback Therapeutics has been acquired and merged into ARS Pharmaceuticals
- 12 May 2022 Silverback Therapeutics plans a phase I trial for Hepatitis B (Parenteral) in the first quarter of 2023
- 31 Mar 2022 Silverback Therapeutics plans to initiate IND-enabling toxicology studies in the fourth quarter of 2022.